Predictive Oncology Issues Letter to Shareholders
Signature of Raymond F. Vennare, Chief Executive Officer Signature of Raymond F. Vennare, Chief Executive OfficerEAGAN, Minn., March 09, 2023...
Financial
Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence
EAGAN, Minn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) and Cvergenx, Inc. today announced an agreement to...
Predictive Oncology launches ACE program to partner with academic and research institutions to advance their drug discovery initiatives
First round of applications due March 31, 2023EAGAN, Minn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today...
SciSparc’s Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
MitoCareX established its initial cloud-based computing infrastructure TEL AVIV, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC)...
MediGO Named as a Finalist in the Prestigious 2023 Edison Awards™
Organ TeamLink™ software solution honored for excellence in the Manufacturing and Logistics categoryBALTIMORE, Feb. 14, 2023 (GLOBE NEWSWIRE) -- MediGO,...
DiagnaMed Prioritizes Development and Commercialization Initiatives for CERVAI™, a Brain Health AI Platform Leveraging Generative AI
CERVAI™ to be available in May 2023TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”)...
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy Cord blood-derived T-Cell Receptor...
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
PHILADELPHIA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 11 posters...
Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer
Dr. Pamela Bush Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer EAGAN, Minn., Feb. 03, 2023 (GLOBE...
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue...
Vyant Bio Commences a Cash Preservation Plan Including a Reduction in Force
Continuing to Explore Strategic Alternatives CHERRY HILL, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”)...
BenchSci Announces Launch of ASCEND™ – a First-of-its-Kind ‘Map’ of All Disease Biology that Aims to Transform Pharmaceutical Research
The SaaS solution is powered by proprietary machine-learning technology that reads and interprets data like a PhD scientist BenchSci ASCEND...
DiagnaMed Holdings Provides Update for BRAIN AGE™ Development and Commercialization Milestones for 2023
Complete IRB-approved research study in Q2-2023 Commercialize BRAIN AGE™ in Q4-2023 TORONTO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings...
Precision Neuroscience Raises $41 Million to Build and Scale the Next Generation of Treatments for Neurological Illnesses
The brain–computer interface company advances the industry with plans for a minimally invasive, reversible implant.NEW YORK, Jan. 25, 2023 (GLOBE...
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance...
CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal
Collaboration will support Sanofi’s use of CytoReason’s computational disease models to develop new targets for inflammatory bowel disease (IBD)TEL AVIV,...
OncXerna Therapeutics Announces Final Results and New Xerna™ TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma
Bavituximab plus pembrolizumab combination achieved a 62.5% response rate in biomarker positive subgroup of hepatocellular cancer patients Data reinforce the...
Castellum, Inc. Announces Signing of Non-Binding LOI for East Coast Government Contractor
Castellum, Inc. Announces Signing of Non-Binding LOI for East Coast Government Contractor Castellum, Inc. (NYSE-American: CTM), a cybersecurity, electronic warfare,...
Quris-AI and MBZUAI to launch world-class Bio-AI center in Abu-Dhabi
Abu Dhabi-based collaboration to focus on accelerating the development of new personalized medications using AIABU DHABI, United Arab Emirates, Jan....
MediGO Leadership Selected to Speak at 2023 SXSW Conference to Discuss Innovation in Organ Transplant Supply Chains
CEO and co-founder Scott Plank will moderate a panel featuring MediGO co-founder and transplant surgeon Joseph Scalea MD, LifeGift CEO...